

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Upadacitinib for moderate to severe rheumatoid arthritis ID1400

Matrix of consultees and commentators

| Consultees | Commentators (no right to submit or appeal) |
|---|---|
| <p><u>Company</u></p> <ul style="list-style-type: none"> • AbbVie (upadacitinib) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action on Pain • Arthritis Action • Arthritis & Musculoskeletal Alliance • BackCare • Disability Rights UK • Leonard Cheshire Disability • Muslim Council of Britain • National Rheumatoid Arthritis Society • Pain Concern • Pain Relief Foundation • Pain UK • South Asian Health Foundation • Specialised Healthcare Alliance • Versus Arthritis <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • British Geriatrics Society • British Institute of Musculoskeletal Medicine • British Orthopaedic Association • British Pain Society • British Society for Rheumatology • British Society of Rehabilitation Medicine • Physiotherapy Pain Association • Primary Care Rheumatology Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal Pharmaceutical Society • Royal Society of Medicine | <p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Abbvie (adalimumab) • Accord Healthcare (methotrexate) • ADVANZ Pharma (methotrexate) • Amgen (adalimumab) • Aspire Pharma (leflunomide) • Biogen (adalimumab, etanercept, infliximab biosimilar) • Boehringer Ingelheim International GmbH (adalimumab) • Bristol-Myers Squibb (abatacept) • Celltrion (rituximab biosimilar) • Cipla EU (methotrexate) • Concordia International (methotrexate) • Eli Lilly (baricitinib) • Generics UK (adalimumab, leflunomide) • Genzyme, a sanofi company |

Matrix for the single technology appraisal of upadacitinib for moderate to severe rheumatoid arthritis ID1400. Issue date: May 2019.

| Consultees | Commentators (no right to submit or appeal) |
|--|--|
| <ul style="list-style-type: none"> • Society and College of Radiographers • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • NHS Rotherham CCG • NHS Surrey Downs CCG • Welsh Government | <ul style="list-style-type: none"> (sarilumab) • hameln pharmaceuticals (methotrexate) • Hospira (infliximab biosimilar, methotrexate) • Janssen (golimumab, infliximab) • medac GmbH (leflunomide, methotrexate) • Merck Sharp & Dohme (golimumab, infliximab biosimilar) • Napp (rituximab biosimilar, infliximab biosimilar) • Nordic Pharma (methotrexate) • Orion Pharma (methotrexate) • Pfizer (etanercept, infliximab, methotrexate, sulfasalazine, tofacitinib) • Roche Products (tocilizumab, rituximab) • Rosemont Pharmaceuticals (methotrexate, sulfasalazine) • Sandoz (adalimumab, etanercept, infliximab, methotrexate, rituximab biosimilar, leflunomide) • SANOFI (leflunomide) • Therakind (methotrexate) • UCB Pharma (certolizumab pegol) • Zentiva (leflunomide) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Academy of Medical Sciences • Chronic Pain Policy Coalition • Cochrane Musculoskeletal Group • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales |

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.